- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04841928
Optimizing Psychological Treatment for Pain After Breast Cancer: A Pilot Study
Optimization of Psychological Treatment for Pain After Breast Cancer Using the Multiphase Optimization Strategy (MOST): A Pilot Study
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The present pilot study is a precursor for a following larger trial and aims to evaluate the i) feasibility, ii) validity, and iii) preliminary efficacy of the three treatment components that will be further investigated in a subsequent larger trial. The present pilot study will employ the same design as will be used in the subsequent larger trial, namely the Multiphase Optimization Strategy (MOST). Specifically, in the subsequent larger trial, MOST will be used to evaluate the efficacy and change processes of three psychological treatment components selected from so-called "third wave" cognitive therapies (CTs), which have been shown to be efficacious in the treatment of pain after breast cancer.
The overall hypothesis is that the selected third wave CT components will target key maintaining psychological factors in pain, thus leading to reductions in the primary outcomes of pain intensity and -interference. Specifically, we hypothesize that:
- Mindful attention practices will increase attentional control (i.e., the ability to intentionally focus and intentionally shift one's attention), thereby reducing pain hypervigilance, leading to reductions in pain intensity and -interference.
- Decentering practices will reduce fusion with thoughts (i.e., getting caught up in one's thoughts and acting automatically in response to thoughts), thereby reducing pain catastrophizing, leading to reductions in pain intensity and -interference.
- Values and committed action (i.e., behavior linked to values and goals) will increase acceptance of discomfort and reduce avoidant behavior, leading to reductions in pain intensity and -interference.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Central Denmark Region
-
Aarhus, Central Denmark Region, Danmark, 8000
- Aarhus University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Diagnosis of primary breast cancer stage I-III
- Min. 6 months post breast cancer treatment (i.e., surgery, chemotherapy, and/or radiotherapy). Endocrine treatment, e.g., Letrozole or Tamoxifen, and/or Zoledronic acid and/or Herceptin treatment is allowed during study participation
- Pain corresponding to a min. pain score of >= 3 on pain intensity or pain interference measured by 11-point Numeric Rating Scales (NRSs)
- Sufficient ability to communicate in Danish
- Sufficient ability to participate in an online-delivered intervention
Exclusion Criteria:
- Metastatic breast cancer (stage IV)
- Breast cancer recurrence
- Bilateral breast cancer
- Other current cancer disease
- Other current pain condition (e.g., fibromyalgia)
- Current severe psychiatric disorder (e.g., psychosis)
- Inability to communicate in Danish
- Inability to participate in an online-delivered intervention
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Venteliste kontrol
Deltagere randomiseret til tilstand 1 tilbydes ikke nogen behandlingskomponenter umiddelbart efter tilmelding, men vil blive tilbudt en behandlingskomponent efter eget valg ved afslutningen af undersøgelsen.
Samlet antal sessioner: 2 (2 kontakttimer) efter studiets afslutning.
|
|
|
Eksperimentel: Opmærksom opmærksomhed
Deltagere randomiseret til tilstand 2 vil modtage komponenten Mindful opmærksomhedsbehandling.
Samlet antal sessioner: 2 (2 kontakttimer).
|
Mindful opmærksomhedsbehandlingskomponenten består af en åndedrætsøvelse og operationaliseres som to sessioner (1 time hver) leveret over to uger, dvs. en session om ugen, med hjemmearbejde mellem sessionerne.
Sessioner vil blive leveret online.
|
|
Eksperimentel: Decentrering
Deltagere, der er randomiseret til tilstand 3, vil modtage decentrerende behandlingskomponent.
Samlet antal sessioner: 2 (2 kontakttimer).
|
Behandlingskomponenten Decentering består af en guidet billedøvelse og operationaliseres som to sessioner (1 time hver) leveret over to uger, dvs. en session om ugen, med hjemmearbejde mellem sessionerne.
Sessioner vil blive leveret online.
|
|
Eksperimentel: Værdier og engageret handling
Deltagere randomiseret til tilstand 4 vil modtage behandlingskomponenten Værdier og engageret handling.
Samlet antal sessioner: 2 (2 kontakttimer).
|
The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions.
Sessions will be delivered online.
|
|
Eksperimentel: Mindful attention + Decentering
Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component.
Total number of sessions: 4 (4 contact hours).
|
Mindful opmærksomhedsbehandlingskomponenten består af en åndedrætsøvelse og operationaliseres som to sessioner (1 time hver) leveret over to uger, dvs. en session om ugen, med hjemmearbejde mellem sessionerne.
Sessioner vil blive leveret online.
Behandlingskomponenten Decentering består af en guidet billedøvelse og operationaliseres som to sessioner (1 time hver) leveret over to uger, dvs. en session om ugen, med hjemmearbejde mellem sessionerne.
Sessioner vil blive leveret online.
|
|
Eksperimentel: Mindful attention + Values and committed action
Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component.
Total number of sessions: 4 (4 contact hours).
|
Mindful opmærksomhedsbehandlingskomponenten består af en åndedrætsøvelse og operationaliseres som to sessioner (1 time hver) leveret over to uger, dvs. en session om ugen, med hjemmearbejde mellem sessionerne.
Sessioner vil blive leveret online.
The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions.
Sessions will be delivered online.
|
|
Eksperimentel: Decentering + Values and committed action
Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component.
Total number of sessions: 4 (4 contact hours).
|
Behandlingskomponenten Decentering består af en guidet billedøvelse og operationaliseres som to sessioner (1 time hver) leveret over to uger, dvs. en session om ugen, med hjemmearbejde mellem sessionerne.
Sessioner vil blive leveret online.
The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions.
Sessions will be delivered online.
|
|
Eksperimentel: Mindful attention + Decentering + Value-based action
Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component.
Total number of sessions: 6 (6 contact hours).
|
Mindful opmærksomhedsbehandlingskomponenten består af en åndedrætsøvelse og operationaliseres som to sessioner (1 time hver) leveret over to uger, dvs. en session om ugen, med hjemmearbejde mellem sessionerne.
Sessioner vil blive leveret online.
Behandlingskomponenten Decentering består af en guidet billedøvelse og operationaliseres som to sessioner (1 time hver) leveret over to uger, dvs. en session om ugen, med hjemmearbejde mellem sessionerne.
Sessioner vil blive leveret online.
The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions.
Sessions will be delivered online.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain intensity (11-point Numeric Rating Scale, NRS)
Tidsramme: Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
The NRS is a validated, self-report instrument assessing pain intensity during the last week.
Answer format range: 0 (no pain) to 10 (worst possible pain); total score range: 0-10.
Higher scores yield more pain.
|
Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
|
Pain interference (the 7-item subscale of the Brief Pain Inventory, BPI)
Tidsramme: Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
The BPI is a validated, self-report instrument assessing clinical pain.
The BPI pain interference subscale assesses pain interference during the last week across 7 domains, i.e., general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life.
Answer format range: 0 (no interference) to 10 (maximal interference); total score range: 0-10.
Higher scores yield more pain interference.
|
Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Smertekvalitet (de 22-elements smertebeskrivelser fra McGill Pain Questionnaire, MPQ)
Tidsramme: Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
Smertedeskriptorerne fra MPQ udgør et valideret, selvrapporterende instrument, der vurderer smertekvalitet (dvs. smertetype, nemlig kontinuerlig smerte, intermitterende smerte, neuropatisk smerte, affektiv smerte) i løbet af den sidste uge.
Svarformatinterval: 0 (ingen smerte) til 10 (værst mulig smerte); Samlet scoreområde: 0-60 (kontinuerlig, neuropatisk og intermitterende smerte), 0-40 (affektiv smerte).
Højere score giver mere smerte.
|
Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
|
Smertekatastrofer (den 13-elementer Pain Catastrophizing Scale, PCS)
Tidsramme: Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
PCS er et valideret, selvrapporterende instrument, der vurderer smertekatastrofer.
Svarformatinterval: 0 (slet ikke) til 4 (hele tiden); samlet scoreinterval: 0-52.
Højere score giver mere smertekatastrofer.
|
Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
|
Frygt for gentagelse af kræft (Fear of Cancer Recurrence Inventory med 9 punkter, FCRI)
Tidsramme: Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
FCRI er et valideret, selvrapporteringsinstrument, der vurderer frygt for gentagelse af kræft i løbet af den sidste måned.
Svarformatinterval: 0 (slet ikke) til 4 (meget); samlet score mellem 0-36.
Højere score giver mere frygt for gentagelse af kræft.
|
Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
|
Trivsel (WHO-5 Well-Being Index med 5 punkter, WHO-5)
Tidsramme: Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
WHO-5 er et valideret, selvrapporterende instrument, der vurderer nuværende velvære.
Svarformatinterval: 0 (på intet tidspunkt) til 5 (hele tiden); samlet scoreinterval: 0-100.
Højere score giver mere velvære.
|
Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
|
Pain intensity (11-point Numeric Rating Scale, NRS)
Tidsramme: Every day for 6 days following the first session (Td) for each treatment component
|
Pain intensity during the last 24 hours will be assessed every day for 6 days following the first session (Td) for each treatment component using the NRS.
Answer format range: 0 (no pain) to 10 (worst possible pain); total score range: 0-10.
Higher scores yield more pain.
|
Every day for 6 days following the first session (Td) for each treatment component
|
|
4. Pain interference (1 aggregated item assessing pain interference during the last 24 hours within the 7 domains measured with the Brief Pain Inventory, BPI, interference subscale)
Tidsramme: Every day for 6 days following the first session (Td) for each treatment component
|
Pain interference during the last 24 hours will be assessed every day for 6 days following the first session (Td) for each treatment component using 1 aggregated item assessing pain interference across the 7 domains measured with the BPI interference subscale, i.e., general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life.
Answer format range: 0 (no interference) to 10 (maximal interference); total score range: 0-10.
Higher scores yield more pain interference.
|
Every day for 6 days following the first session (Td) for each treatment component
|
|
Pain burden (11-point Numeric Rating Scale, NRS)
Tidsramme: Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
The NRS is a validated, self-report instrument assessing pain burden during the last week.
Answer format range: 0 (no burden) to 10 (maximal burden); total score range: 0-10.
Higher scores yield more pain burden.
|
Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
|
Psychological distress (the 14-item Hospital Anxiety and Depression Scale, HADS)
Tidsramme: Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
The HADS is a validated, self-report instrument assessing psychological distress during the last week.
Answer format range: 0 (not at all or never) to 3 (most or all of the time); total score range 0-42.
Higher scores yield more distress.
|
Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Moderator: Terapeutisk alliance (den 12-elementer Working Alliance Inventory, WAI) Revided Short Form
Tidsramme: 1 uge efter sidste session (Post-intervention, T2)
|
WAI er et valideret, selvrapporteringsinstrument, der vurderer terapeutisk alliance.
Svarformatinterval: 1 (aldrig) til 7 (hele tiden); samlet scoreinterval: 12-84.
Højere score giver en stærkere terapeutisk alliance.
|
1 uge efter sidste session (Post-intervention, T2)
|
|
Mediator: Mindful opmærksomhed (mindful Attention Awareness Scale med 15 punkter, MAAS)
Tidsramme: Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
MAAS er et valideret selvrapporteringsinstrument, der vurderer individuelle forskelle i hyppigheden af opmærksomme tilstande over tid.
Svarformatinterval: 1 (næsten altid) til 6 (næsten aldrig); samlet scoreinterval: 1-6.
Højere score giver højere niveauer af opmærksom opmærksomhed.
|
Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
|
Formidler: Mindful opmærksomhed (2 punkter fra 15-punkters Mindful Attention Awareness Scale, MAAS)
Tidsramme: Før hver session (Ts)
|
MAAS punkt 13 og 7 vil blive vurderet før hver session (Ts).
Svarformatinterval: 1 (næsten altid) til 6 (næsten aldrig).
Højere score giver højere niveauer af opmærksom opmærksomhed.
|
Før hver session (Ts)
|
|
Mediator: Smerteaccept og aktivitetsengagement (20-element Chronic Pain Acceptance Scale, CPAS)
Tidsramme: Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
CPAS er et valideret, selvrapporterende instrument, der vurderer smerteaccept og aktivitetsengagement.
Svarformatinterval: 0 (aldrig sandt) til 6 (altid sandt); subskala scoreområde: 0-54 (smerteaccept subskala), 0-66 (aktivitetsengagement subskala).
Højere score giver mere accept og aktivitetsengagement.
|
Baseline (T1) til 1 uge efter sidste session (Post-intervention, T2)
|
|
Qualitative Interviews
Tidsramme: 10-14 days after last session
|
Participants will be invited to participate in a 30-minutes semi-structured individual interview 10-14 days after their last session.
The interview serves to support the validation of the treatment components and to provide in-depth knowledge about the participants' experiences through their qualitative comments.
|
10-14 days after last session
|
|
Moderator: Demographic characteristics
Tidsramme: Baseline (T1)
|
Socio-demographic characteristics will be assessed using single questions (e.g., municipality, marital status, income, work status).
|
Baseline (T1)
|
|
Moderator: Clinical characteristics
Tidsramme: Baseline (T1)
|
Clinical characteristics will be assessed using single questions (e.g., date of surgery, adjuvant therapy).
|
Baseline (T1)
|
|
Moderator: Treatment expectancy
Tidsramme: Baseline (T1)
|
Treatment expectancy will be assessed using a single question regarding the extent to which the participant believes that the intervention will reduce pain and increase overall well-being.
Answer format range: 1 (not at all) to 5 (a great deal); total score range: 1-5.
Higher scores indicate stronger expectations that the intervention will lead to a positive outcome.
|
Baseline (T1)
|
|
Moderator: Home work
Tidsramme: Before each session (Ts) and 1 week after last session (Post-intervention, T2)
|
Homework will be assessed with 4 single items related to i) whether home work has been conducted (yes/no), and the ii) type, iii) frequency (number of days per week), and iv) duration of completed homework (average number of minutes per day).
|
Before each session (Ts) and 1 week after last session (Post-intervention, T2)
|
|
Mediator: Mindful attention (1 item from the 15-item Mindful Attention Awareness Scale, MAAS)
Tidsramme: Every day for 6 days following the first session for each treatment component (Td)
|
MAAS item 6 will be assessed every day for 6 days following the first session (Td) for each treatment component.
Answer format range: 1 (almost always) to 6 (almost never).
Higher scores yield higher levels of mindful attention.
|
Every day for 6 days following the first session for each treatment component (Td)
|
|
Mediator: Decentering (the 11-item subscale of the Experiences Questionnaire, EQ)
Tidsramme: Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
The EQ is a validated, self-report instrument assessing decentering.
Answer format range: 1 (do not agree at all) to 5 (agree completely); total score range: 11-55.
Higher scores yield higher levels of decentering.
|
Baseline (T1) to 1 week after last session (Post-intervention, T2)
|
|
Mediator: Decentering (2 items from the 11-item subscale of the Experiences Questionnaire, EQ)
Tidsramme: Before each session (Ts)
|
EQ items 5 and 7 will be assessed before each session (Ts).
Answer format range: 1 (do not agree at all) to 5 (agree completely).
Higher scores yield higher levels of decentering.
|
Before each session (Ts)
|
|
Mediator: Decentering (1 item from the 11-item subscale of the Experiences Questionnaire, EQ)
Tidsramme: Every day for 6 days following the first session for each treatment component (Td)
|
EQ item 5 will be assessed every day for 6 days following the first session (Td) for each treatment component.
Answer format range: 1 (do not agree at all) to 5 (agree completely).
Higher scores yield higher levels of decentering.
|
Every day for 6 days following the first session for each treatment component (Td)
|
|
Mediator: Pain acceptance and activity engagement (2 items from the 20-item Chronic Pain Acceptance Scale, CPAS)
Tidsramme: Before each session (Ts)
|
CPAS items 1 and 12 will be assessed before each session (Ts).
Answer format range: 0 (never true) to 6 (always true).
Higher scores yield more acceptance and activity engagement.
|
Before each session (Ts)
|
|
Mediator: Pain acceptance and activity engagement (1 item from the 20-item Chronic Pain Acceptance Scale, CPAS)
Tidsramme: Every day for 6 days following the first session for each treatment component (Td)
|
CPAS item 1 will be assessed every day for 6 days following the first session (Td) for each treatment component.
Answer format range: 0 (never true) to 6 (always true).
Higher scores yield more acceptance and activity engagement.
|
Every day for 6 days following the first session for each treatment component (Td)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Maja Johannsen, PhD, University of Aarhus
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MOST Pain Pilot
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
The First Affiliated Hospital of Xiamen UniversityIkke rekrutterer endnuLocally Advanced Breast Cancer (LABC)
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Beijing Bio-Targeting Therapeutics Technology Co...Trukket tilbage
-
Indonesia UniversityIkke rekrutterer endnuPræhabilitering | Postoperativ inflammation | Locally Advanced Breast Cancer (LABC)Indonesien
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
Atlas UniversityIkke rekrutterer endnuBrystkræft | Locally Advanced Breast Cancer (LABC)Tyrkiet (Türkiye)
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Second Affiliated Hospital, School of Medicine,...RekrutteringTNBC, Triple Negative Breast CancerKina
Kliniske forsøg med Opmærksom opmærksomhed
-
University of HoustonAfsluttetPsykiske lidelser | Trauma | Post traumatisk stress syndrom | Mindfulness | BrandmændForenede Stater
-
Tel Aviv UniversityAfsluttet
-
San Diego State UniversityAfsluttetStresslidelser, posttraumatiskForenede Stater
-
San Diego State UniversityAfsluttetStresslidelser, posttraumatiskForenede Stater
-
London Metropolitan UniversityAfsluttetSeksuelle smerteforstyrrelserDet Forenede Kongerige
-
University of Texas at TylerPsi Chi; Sarah Sass, PhDAktiv, ikke rekrutterende
-
University of South CarolinaCenters for Disease Control and PreventionRekrutteringKognitiv funktion | Opførsel, sundhed | Alder godtForenede Stater
-
The Miriam HospitalRhode Island FoundationIkke rekrutterer endnuEndometriose | Bækkensmerter
-
Yeshiva UniversityYale UniversityAfsluttetAnoreksi | Bulimia nervosa | Anorexia Nervosa, atypisk | Bulimi; AtypiskForenede Stater
-
VA Office of Research and DevelopmentAfsluttet